跳至主要内容
临床试验/NCT03304847
NCT03304847招募中不适用

Arrhythmogenic Substrate Assessment in Patients With Primary Cardiomyopathies and/or Channellopaties With and Without History of Brugada Syndrome: A Prospective Follow-up Study

IRCCS Policlinico S. Donato2 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2018年1月24日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
35
试验地点
2
主要终点
Freedom from ventricular fibrillation or ventricular tachycardia

研究概览

简要总结

This study assesses the value of arrhythmogenic substrate identification and elimination by catheter ablation to prevent recurrent ventricular arrhythmias and sudden cardiac death in a series of selected patients with primary cardiomyopathy and/or channellopaties with ICD implantation.

详细描述

The present study is designed as a prospective single center study. All selected patients with implanted ICD to prevent VT/VF recurrence who are referred to the Arrhythmology Department of San Donato Milanese Hospital, for the management of a primary cardiomyopathy fulfilling the inclusion criteria will be enrolled. Primary cardiomyopathies include: - dilated cardiomyopathy (DCM), - arrhythmogenic right ventricular cardiomyopathy (ARVC), - left ventricular non-compaction (LVNC), - early repolarization syndrome (ER), and - hypertrophic cardiomyopathy (HCM).Channellopaties incude - Long QT syndrome and J-wave syndrome) Patients with or without a family history of BrS, will also be included. Endo-epicardial electroanatomical 3Dmapping and RFA ablation will be systematically performed according to a standardized procedure. Patients will be monitored for at least 3 days after RF ablation. Before hospital discharge, echocardiography and 12-lead ECG will be performed. Patients will be followed-up clinically after the procedure as per normal clinical practice. Follow-up visits will be systematically scheduled at 3, 6, 12, 18 and 24 months. 12-lead ECG and ICD interrogation will be performed at each follow-up visit. Patients will be instructed to immediately contact the center in case of symptoms suggestive of ventricular arrhythmias. Documentation for intercurrent events will be requested and collected. The maximal duration of study participation for the individual patients is two years.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients affected by cardiomyopathies and/or channellopaties (long QT syndrome and J-wave syndrome) with and without documented family history of BrS;
  • Presence of symptoms attributable to VA and/or presenting documented arrhythmic episodes;
  • Patients with an ICD already implanted;
  • Patients referred to the centre for an electrophysiological study and indication for a potential concomitant radio-frequency catheter ablation (RFA) of ventricular tachycardia (VT) or ventricular fibrillation (VF);
  • Age ≥ 18;
  • Willingness to attend follow-up examinations;
  • Written informed consent for the participation in the trial

排除标准

  • Pregnancy or breast-feeding;
  • Life expectancy < 12 months

结局指标

主要结局

Freedom from ventricular fibrillation or ventricular tachycardia

时间窗: two years

Survival from recurrent ventricular arrhythmias

次要结局

  • Measurements of Areas of prolonged ventricular potentials obtained by electroamatomocal maps before and after ablation(1 day)

研究者

发起方
IRCCS Policlinico S. Donato
申办方类型
Other
责任方
Principal Investigator
主要研究者

Carlo Pappone

Chief of Arrhythmology Deartment

IRCCS Policlinico S. Donato

研究点 (2)

Loading locations...

相似试验